TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
Shah MV, Tran ENH, Shah S, Chhetri R, Baranwal A, Ladon D, Shultz C, Al-Kali A, Brown AL, Chen D, Scott HS, Greipp P, Thomas D, Alkhateeb HB, Singhal D, Gangat N, Kumar S, Patnaik MM, Hahn CN, Kok CH, Tefferi A, Hiwase DK.
Shah MV, et al. Among authors: alkhateeb hb.
Blood Cancer J. 2023 Apr 11;13(1):51. doi: 10.1038/s41408-023-00821-x.
Blood Cancer J. 2023.
PMID: 37041128
Free PMC article.